Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Confirmation Hearings Expected To Include Questions On Utah Medicaid Waiver

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Utah Governor Michael Leavitt expects to face intense questioning from Senators regarding a reduction in Medicaid benefits that allowed for expanding the covered population. Leavitt's early priorities are understood to include addressing drug safety issues, but naming a permanent FDA commissioner may be less pressing for nominee than changes at CDC and HRSA.

You may also be interested in...



Leavitt To Face Questioning In Senate Finance, Health Committees

Bush Administration nominee Michael Leavitt will face questioning from two Senate committees in his bid to succeed HHS Secretary Tommy Thompson

HHS Secretary Nominee Leavitt Could Increase Focus On Medicaid Reform

President Bush nominates EPA Administrator Mike Leavitt to succeed Tommy Thompson as HHS secretary. Leavitt gained attention for his Medicaid reform initiatives during his time as Utah governor and helped develop the Bush Administration's 2003 Medicaid proposal.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel